/Emerson%20Electric%20Co_%20sign%20on%20building-by%20SNEHIT%20PHOTO%20via%20Shutterstock.jpg)
Saint Louis, Missouri-based Emerson Electric Co. (EMR) is a technology and software company. Valued at a market cap of $78.9 billion, the company designs and manufactures industrial automation equipment, climate control systems, precision measurement instruments, and software for process and hybrid industries. It is scheduled to announce its fiscal Q3 earnings for 2025 before the market opens on Wednesday, Aug. 6.
Before this event, analysts project this technology and engineering company to report a profit of $1.51 per share, up 5.6% from $1.43 per share in the year-ago quarter. The company has a solid trajectory of consistently surpassing Wall Street’s bottom-line estimates in each of the last four quarters. Its earnings of $1.48 per share in the previous quarter topped the consensus estimates by 4.2%.
For the full year, analysts expect EMR to report EPS of $6, up 9.3% from $5.49 in fiscal 2024. Its EPS is expected to further grow 7.7% year-over-year to $6.46 in fiscal 2026.
Shares of EMR have soared 18% over the past 52 weeks, outperforming both the S&P 500 Index's ($SPX) 10.5% uptick and the Industrial Select Sector SPDR Fund’s (XLI) 17.3% return over the same time frame.
On May 7, EMR’s shares surged 2.4% after its better-than-expected Q2 earnings release. The company’s revenue improved 1.3% year-over-year to $4.4 billion and topped the consensus estimates by 1.1%. Moreover, its adjusted EPS came in at $1.48, up 8.8% from the year-ago quarter and 4.2% above the analyst expectations. Strong growth in underlying orders and a notable 200 basis-point year-over-year increase in its adjusted segment EBITA margin to a record 28% acted as tailwinds in the quarter.
Wall Street analysts are moderately optimistic about EMR’s stock, with a "Moderate Buy" rating overall. Among 24 analysts covering the stock, 17 recommend "Strong Buy," one indicates a "Moderate Buy," four suggest "Hold,” one advises a "Moderate Sell,” and one suggests a “Strong Sell” rating. The mean price target for EMR is $143.42, indicating a 2.2% potential upside from the current levels.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
